| Literature DB >> 21637674 |
Lucimari Bizari1, Eloiza Helena Tajara, Ana Elizabete Silva.
Abstract
Interphase chromosomes have been shown to occupy discrete regions of the nucleus denominated chromosome territories (CTs), their active genes being preferentially positioned on the surfaces of these CTs, where they are accessible to transcriptional machinery. By means of FISH (Fluorescence in situ Hybridization), we analyzed the CCND1 and HER-2/neu gene positions within the CTs and their relationship with gene amplification and protein over-expression in esophageal and gastric cancers. The CCND1 and HER-2/Neu genes were more often positioned at the periphery (mean frequency of 60%-83%) of the CTs in tumor tissues of the esophagus and stomach. Moreover, this positioning revealed no association with either gene amplification or the protein over-expression status of these genes, although, in esophageal carcinoma, Kappa statistics showed a moderate agreement between amplification of the CCND1 gene (Kappa = 0.400) and its location within the CT, as well as with over-expression of the corresponding protein (Kappa = 0.444). Thus, our results suggest that gene positioning in interphase chromosomes does not follow a definitive pattern neither does it depend only on gene transcriptional activity. Apparently, this positioning could be both gene- and tissue-specific, and depends on other factors acting together, such as dense-gene, chromosome size, chromatin structure, and the level and stability of its expression.Entities:
Keywords: CCND1; HER-2/neu; chromosome territories; esophageal carcinoma; gastric cancer
Year: 2009 PMID: 21637674 PMCID: PMC3036938 DOI: 10.1590/S1415-47572009005000034
Source DB: PubMed Journal: Genet Mol Biol ISSN: 1415-4757 Impact factor: 1.771
Results on the location of CCND1 and HER-2/neu genes in chromosome territories, and amplification and protein over-expression in normal and tumor tissues of the esophagus.
| Samples | Position in CT
| Amplification (G/C>2.0) | Over- | Position in CT
| Amplification (G/C>2.0) | Over- | |||||
| I (%) | P (%) | Category | I (%) | P (%) | Category | ||||||
| Normal mucus | |||||||||||
| MNE 01 | 65.1 | 34.9 | I | 0.9 | 35.4 | 63 | 37 | I | 1.0 | 0 | |
| MNE 02 | 24 | 75.8 | P | 1.0 | 25.2 | 68.5 | 31.4 | I | 0.9 | 0 | |
| MNE 03 | 76.5 | 23.4 | I | 0.9 | 25.4 | 74.2 | 25.8 | I | 0.9 | 0 | |
| MNE 04 | 36.2 | 63.7 | P | 0.9 | 20.4 | 67.3 | 32.6 | I | 0.9 | 0 | |
| MNE 05 | 19.7 | 80.3 | P | 0.9 | 12.2 | 59.7 | 40.2 | I | 1.0 | 0 | |
| (
| 44.30 ± 25.26 | 55.62 ± 25.24 | 66.54 ± 5.53 | 33.4 ± 5.51 | |||||||
| Esophageal carcinoma | |||||||||||
| CE 01 | 3 | 97 | P | 20.4 | 22 | 77.9 | P | 1.0 | 1+ | ||
| CE 02 | 2.9 | 96.9 | P | 22.2 | 20 | 79.9 | P | 1.0 | 0 | ||
| CE 03 | 67.1 | 32.8 | I | 0.9 | 10.6 | 56 | 44 | I | 0.7 | 0 | |
| CE 04 | 77.2 | 22.7 | I | 0.9 | 11.8 | 11.2 | 88.7 | P | 0 | ||
| CE 05 | 2.9 | 96.9 | P | 71.7 | 28.3 | I | 1.0 | 1+ | |||
| CE 06 | 74 | 25.4 | I | 1.0 | 2.0 | 45.5 | 54.5 | P | 0.9 | 0 | |
| CE 07 | 74.6 | 25.4 | I | 22.3 | 12.2 | 87.7 | P | 3+ | |||
| CE 08 | 25 | 75 | P | 0.9 | 32.0 | 71.7 | 28.2 | I | 0 | ||
| CE 09 | 27.9 | 72.1 | P | 1.8 | 0 | 46.1 | 54 | P | 0.9 | 0 | |
| CE 10 | 38.8 | 61.3 | P | 35.4 | 64.6 | P | 0.9 | 3+ | |||
| (
| 39.34 ± 31.55 | 60.55 ± 31.36 | 39.18 ± 22.78 | 60.78 ± 22.75 | |||||||
| p value | 0.5033 | 0.0100 | |||||||||
Abbreviations: CT: chromosome territories; I: internal; P: peripheral; G/C: gene-to-centromere ratio.
Results on location of CCND1 and HER-2/neu genes in chromosome territories, and amplification and protein over-expression in normal and tumor tissues of the stomach.
| Samples | Position in CT
| Amplification (G/C>2.0) | Over- | Position in CT
| Amplification (G/C>2.0) | Over- | |||||
| I (%) | P (%) | Category | I (%) | P (%) | Category | ||||||
| Normal mucus | |||||||||||
| MNG 01 | 46 | 54 | P | 1.0 | 14.2 | 24.6 | 75.4 | P | 0.9 | 0 | |
| MNG 02 | 25 | 75 | P | 1.0 | 8.8 | 31 | 69 | P | 0.9 | 0 | |
| MNG 03 | 76.3 | 23.7 | I | 0.9 | 7.6 | 33 | 67 | P | 1.0 | 0 | |
| MNG 04 | 76.7 | 23.2 | I | 0.9 | 6.1 | 42 | 58 | P | 0.9 | 0 | |
| MNG 05 | 24.6 | 75.3 | P | 0.9 | 12.8 | 73.6 | 26.4 | I | 0.9 | 0 | |
| (
| 49.72 ± 25.93 | 50.24 ± 25.93 | 40.84 ± 19.34 | 59.16 ± 19.34 | |||||||
| Gastric cancer | |||||||||||
| CG 01 | 12.2 | 87.7 | P | 1.5 | 22.5 | 36.6 | 63.4 | P | 0.9 | 0 | |
| CG 02 | 7.4 | 92.4 | P | 1.0 | 5.6 | 60 | 40 | I | 1.7 | 2+ | |
| CG 03 | 47.3 | 52.6 | P | 0.9 | 5.2 | 34.8 | 65.1 | P | 0.9 | 0 | |
| CG 04 | 1.6 | 98.3 | P | 0.9 | 25.6 | 24.6 | 75.2 | P | 0.9 | 0 | |
| CG 05 | 9 | 90.9 | P | 1.0 | 20.2 | 29.8 | 70.1 | P | 1.0 | 0 | |
| CG 06 | 15 | 85 | P | 1.0 | 27.6 | 19.3 | 80.5 | P | 1.0 | 0 | |
| CG 07 | 25.9 | 74 | P | 1.0 | 17.2 | 38.7 | 61.3 | P | 0.9 | 0 | |
| CG 08 | 17.9 | 82.1 | P | 0.9 | 35.0 | 25 | 74.9 | P | 1.0 | 0 | |
| CG 09 | 12.3 | 87.6 | P | 1.0 | 0.0 | 25.4 | 74.5 | P | 0.9 | 0 | |
| CG 10 | 13.2 | 86.7 | P | 0.9 | 12.0 | 37.8 | 62.2 | P | 0.9 | 0 | |
| (
| 16.18 ± 12.68 | 83.73 ± 12.67 | 33.20 ± 11.50 | 66.72 ± 11.44 | |||||||
| p value | < 0.0001 | 0.0017 | |||||||||
Abbreviations: CT: chromosome territories; I: internal; P: peripheral; G/C: gene-to-centromere ratio.
Figure 1Fluorescence insitu hybridization (FISH): (A) CCND1 gene (red signal) in the internal region of chromosome 11 territory (green) in normal esophageal mucus; (B) CCND1 gene (red signal) located at the periphery or external to chromosome 11 territory (green) in gastric adenocarcinoma; (C) HER-2/neu gene (red signal) located at the periphery or external to chromosome 17 territory (green) in esophageal carcinoma: (D) CCND1 gene amplification (red cluster) located in the external region of chromosome 11 territory (green) in esophageal carcinoma.
Relationship between gene location (peripheral or internal) of CCND1 in chromosome 11 territory, and amplification and over-expression in esophageal carcinoma and gastric adenocarcinoma.
| Samples/ | Amplification (FISH)
| Over-expression (IHC)
| |||||
| Total | Cyclin D1 (+) | Cyclin D1 (-) | Total | ||||
| Esophageal carcinoma | |||||||
| Peripheral | 4 (40%) | 2 (20%) | 6 (60%) | 3 (30%) | 3 (30%) | 6 (60%) | |
| Internal | 1 (10%) | 3 (30%) | 4 (40%) | 0 (0%) | 4 (40%) | 4 (40%) | |
| Total | 5 (50%) | 5 (50%) | 10 (100%) | 3 (30%) | 7 (70%) | 10 (100%) | |
| Kappa | 0.400* | 0.444* | |||||
| p value | 0.088 | 0.091 | |||||
| Gastric cancer | |||||||
| Peripheral | 0 (0%) | 10 (100%) | 10 (100%) | 5 (50%) | 5 (50%) | 10 (100%) | |
| Internal | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| Total | 0 (0%) | 10 (100%) | 10 (100%) | 5 (50%) | 5 (50%) | 10 (100%) | |
| Kappa | a | a | |||||
| p value | a | a | |||||
*Value of Kappa = 0.40-0.59: moderated agreement. a value of Kappa or p not estimated. FISH: Fluorescence in situ hybridization. IHC: immunohistochemical.
Relationship between gene location (peripheral or internal) of HER-2/ neu in chromosome 17 territory, and amplification and over-expression, in esophageal carcinoma and gastric adenocarcinoma.
| Samples/ | Amplification (FISH)
| Over-expression (IHC)
| |||||
| Total | Her-2/neu (+) | Her-2/neu (-) | Total | ||||
| Esophageal Carcinoma | |||||||
| Peripheral | 2 (20%) | 5 (50%) | 7 (70%) | 2 (20%) | 5 (50%) | 7 (70%) | |
| Internal | 1 (10%) | 2 (20%) | 3 (30%) | 0 (0%) | 3 (30%) | 3 (30%) | |
| Total | 3 (30%) | 7 (70%) | 10 (100%) | 2 (20%) | 8 (80%) | 10 (100%) | |
| Kappa | -0.034* | 0.194** | |||||
| p value | a | 0.301 | |||||
| Gastric cancer | |||||||
| Peripheral | 0 (0%) | 9 (90%) | 9(90%) | 0 (0%) | 9 (90%) | 9 (90%) | |
| Internal | 0 (0%) | 1 (10%) | 1 (10%) | 1 (10%) | 0 (0%) | 1 (10%) | |
| Total | 0 (0%) | 10 (100%) | 10 (100%) | 1 (10%) | 9 (90%) | 10 (100%) | |
| Kappa | a | -0.22* | |||||
| p value | a | a | |||||
*Value of Kappa < 0: no agreement. **Value of Kappa = 0-0.19: slightpoor agreement. a value of Kappa or p not estimated. FISH: Fluorescence in situ hybridization. IHC: immunohistochemical.